Silco Pharmaceuticals Limited (DSE:SILCOPHL)
Bangladesh flag Bangladesh · Delayed Price · Currency is BDT
14.40
-0.20 (-1.37%)
At close: Apr 13, 2026

Silco Pharmaceuticals Cash Flow Statement

Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Net Income
42.442.6545.8869.2284.4584.65
Depreciation & Amortization
93.6593.6593.2290.5378.4978.4
Loss (Gain) From Sale of Investments
0.930.930.72-18.56-6.48-0.42
Other Operating Activities
-72.93-61.317.6713.2216.77-9.2
Change in Accounts Receivable
6.766.76-42.0911.731.394.46
Change in Inventory
-6.57-6.570.0513.7-8.395.26
Change in Accounts Payable
-0.08-0.08-0.15-2.58-3.82-2.7
Change in Other Net Operating Assets
1.271.27-20.983.226.766.77
Operating Cash Flow
65.4277.384.31180.48169.08257.21
Operating Cash Flow Growth
-40.86%-8.32%-53.29%6.74%-34.26%75.44%
Capital Expenditures
-58.06-69.76-84.26-181.95-106.13-376.43
Investment in Securities
-2.9222.9622.71-28.81136.17
Other Investing Activities
0-0.93-0.7218.566.480.42
Investing Cash Flow
-58.06-67.76-62.01-140.68-128.47-239.83
Long-Term Debt Repaid
--4.58-4.3-4.11-3.77-3.54
Net Debt Issued (Repaid)
-4.81-4.58-4.3-4.11-3.77-3.54
Common Dividends Paid
-6.13-6.75-19.14-31.45-62.62-62.01
Other Financing Activities
-0.45-0.65-0.93-0.2-0.53-0.76
Financing Cash Flow
-11.39-11.97-24.37-35.76-66.93-66.31
Miscellaneous Cash Flow Adjustments
-0--0-00
Net Cash Flow
-4.03-2.44-2.064.05-26.31-48.94
Free Cash Flow
7.367.540.05-1.4762.95-119.22
Free Cash Flow Growth
-13818.79%----
Free Cash Flow Margin
1.71%1.75%0.01%-0.32%11.25%-19.84%
Free Cash Flow Per Share
0.070.070.00-0.010.61-1.15
Cash Interest Paid
0.450.650.930.20.530.76
Cash Income Tax Paid
97.6997.346.736.998.2714.95
Levered Free Cash Flow
-10.44-13.12-11.6736.24-142.51
Unlevered Free Cash Flow
-10.84-12.54-11.5536.57-142.03
Change in Working Capital
1.381.38-63.1726.07-4.15103.78
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.